Performance Evaluation of Two Diagnostic Technologies for TB Detection Based Upon Breath Testing
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pulmonary TB
- Sponsor
- Find
- Enrollment
- 360
- Locations
- 1
- Primary Endpoint
- Microbiological TB Diagnosis
- Last Updated
- 8 years ago
Overview
Brief Summary
This will be a prospective, multicentre study conducted to evaluate the diagnostic accuracy of two TB breath-based technologies independently of the manufacturers. Assay error and failure rates and device operational characteristics will also be assessed during this study. Participants will be enrolled in this study in line with FIND sample banking activities. Results from index tests will not be used to make clinical decisions. Participation in this study will not alter the standard of care.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Symptoms suggesting pulmonary TB, i.e. persistent cough (generally \> 3 weeks or as per local definition of TB suspect) and at least one other finding listed below:
- •Persistent cough
- •Recent weight loss
- •Night sweats
- •Contact w/ active case
- •Loss of appetite
- •Other \[specify\]
- •Provision of informed consent to sample collection, banking and HIV and breath-based assay testing
- •Production of adequate quantity of sputum (sputum induction whenever possible)
- •Adult age (\>18 years old)
Exclusion Criteria
- •Participants receiving any anti-tuberculosis medication, including fluoroquinolone and aminoglycosides in the 60 days prior to enrolment.
- •Participants with ONLY extra-pulmonary disease will be excluded.
- •Participants for whom complete follow-up and a clear final diagnosis are judged to be difficult (e.g. residents elsewhere or about to move).
Outcomes
Primary Outcomes
Microbiological TB Diagnosis
Time Frame: 8 weeks
TB diagnosed by AFB smear microscopy or by one of two MGIT (liquid) or LJ (solid) cultures on enrollment or follow-up sputum sample